| Literature DB >> 6539662 |
P Kajanoja, M Mandelin, U M Mäkilä, O Ylikorkala, C Felding, C Somell, A Olund, H Pedersen.
Abstract
A randomized, double-blind, placebo-controlled, multicentre study was conducted to assess the efficacy and tolerance of a single 1.0 mg Gemeprost (16, 16-dimethyl-trans-delta 2PGE1 methyl ester) vaginal suppository for dilatation of the cervix uteri prior to vacuum aspiration termination of first trimester pregnancy in nulliparous women. The suppository was inserted three hours before vacuum aspiration. In the six centres involved, the preoperative cervical diameter was significantly greater in women treated with Gemeprost. Further mechanical dilatation was either unnecessary or significantly easier than in placebo-treated women. A significant reduction in operative blood loss was noted in the Gemeprost group.Entities:
Keywords: Abortion, Induced; Biology; Carboxylic Acids; Cervical Effects; Cervix; Contraception; Contraceptive Methods--side effects; Data Analysis; Demographic Factors; Double-blind Studies; Endocrine System; Epidemiologic Methods; Evaluation; Family Planning; Fertility; Fertility Control, Postconception; Fertility Measurements; Genitalia; Genitalia, Female; Ingredients And Chemicals; Measurement; Nulliparity; Organic Chemicals; Parity; Physiology; Population; Population Dynamics; Pregnancy; Pregnancy, First Trimester; Prostaglandins--side effects; Reproduction; Research Methodology; Studies; Urogenital System; Uterus; Vacuum Aspiration; Vaginal Spermicides--side effects; Vaginal Suppository--side effects
Mesh：
Substances：
Year: 1984 PMID： 6539662 DOI： 10.1016/s0010-7824(84)80005-0
Source DB: PubMed Journal: Contraception ISSN： 0010-7824 Impact factor: 3.375